A practical reference on peptide backbone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-06. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
=== External phylogeny === Animals are monophyletic, meaning they are derived from a common ancestor. Animals are the sister group to the choanoflagellates, with which they form the Choanozoa. Ros-Rocher and colleagues (2021) trace the origins of animals to unicellular ancestors, providing the external phylogeny shown in the cladogram. Uncertainty of relationships is indicated with dashed lines. The animal clade had certainly originated by 650 mya, and may have come into being as much as 800 mya, based on molecular clock evidence for different phyla.
The company laid off an unspecified number of staffers in March 2005, although Kudirka denied rumors that the company was closing. He soon dissolved 2015 and moved to Florida, returning to Tulsa when he realized he wanted to continue working on video games. Konami Digital Entertainment released Time Ace, developed under the Trainwreck Studios name, in June 2007. On September 24, 2008, Kudirka announced that 2015 had received "several million dollars" in funding from private investors, with which it opened another division, Tornado Studios. The new studio started out with two people, including Kudirka, and sought to make casual games, including for the Wii. At the same time, 2015 was to continue making action games. By March 2009, Tornado Studios had 15 employees and was nearing the release of its first game, Powerbike, through Majesco. The game was released in April under the Trainwreck Studios name. Its first game was Project Runway, initially called World of Fashion until Atari signed to publish it and licensed the series's name. It was released in March 2010. In November, Tornado Studios released Fun with Death for iOS devices. Kudirka said that the rise of digital distribution allowed Tornado Studios to self-publish its games, aiming to release as many games as possible. A third game, Anomaly for personal computers and for the PlayStation 3 via PlayStation Network, was two-thirds-complete by this time and scheduled to be released by April 1, 2011. Tornado Studios had 25 employees, including contractors, at this time.
Arafat Jamal, the UNHCR Representative in Afghanistan, noted that they faced limited options amid the military confrontations between Afghanistan and Pakistan. According to The Guardian, the war has overshadowed the executions of political prisoners in Iran, including those involved in the mass protests of January 2026, allowing Iran to continue carrying out death sentences and other severe punishments with little international scrutiny. According to several Iran-focused human rights groups, the rate of sentencing and executions by hanging surged amidst the war. The groups state that in most of these cases, executed prisoners did not receive due process.
This article records new taxa of fossil mammals of every kind that are scheduled to be described during the year 2026, as well as other significant discoveries and events related to paleontology of mammals that are scheduled to occur in the year 2026.
Sources: en.wikipedia.org
Shear-thickening (dilatant) liquids, whose viscosity increases with the rate of shear strain. Shear-thinning liquids, whose viscosity decreases with the rate of shear strain. Thixotropic liquids, that become less viscous over time when shaken, agitated, or otherwise stressed. Rheopectic liquids, that become more viscous over time when shaken, agitated, or otherwise stressed. Bingham plastics that behave as a solid at low stresses but flow as a viscous fluid at high stresses. Trouton's ratio is the ratio of extensional viscosity to shear viscosity. For a Newtonian fluid, the Trouton ratio is 3. Shear-thinning liquids are very commonly, but misleadingly, described as thixotropic. Viscosity may also depend on the fluid's physical state (temperature and pressure) and other, external, factors. For gases and other compressible fluids, it depends on temperature and varies very slowly with pressure. The viscosity of some fluids may depend on other factors. A magnetorheological fluid, for example, becomes thicker when subjected to a magnetic field, possibly to the point of behaving like a solid.
20 standard amino acids 22 proteinogenic amino acids over 80 amino acids created abiotically in high concentrations about 900 are produced by natural pathways over 118 engineered amino acids have been placed into proteins These groups overlap, but are not identical. All 22 proteinogenic amino acids are biosynthesised by organisms and some, but not all, of them also are abiotic (found in prebiotic experiments and meteorites). Some natural amino acids, such as norleucine, are misincorporated translationally into proteins due to infidelity of the protein-synthesis process. Many amino acids, such as ornithine, are metabolic intermediates produced biosynthetically, but not incorporated translationally into proteins. Post-translational modification of amino acid residues in proteins leads to the formation of many proteinaceous, but non-proteinogenic, amino acids. Other amino acids are solely found in abiotic mixes (e.g. α-methylnorvaline). Over 30 unnatural amino acids have been inserted translationally into proteins in engineered systems, yet are not biosynthetic.
Most charts or tables indicate the type of friction factor, or at least provide the formula for the friction factor with laminar flow. If the formula for laminar flow is f = 16/Re, it is the Fanning factor f, and if the formula for laminar flow is fD = 64/Re, it is the Darcy–Weisbach factor fD. Which friction factor is plotted in a Moody diagram may be determined by inspection if the publisher did not include the formula described above:
Interbake Foods of Richmond, Virginia, produces most of the commercially available hardtack in the United States, under the "Sailor Boy" label. As of January 2015, 98 percent of its production goes to Alaska. Alaskans are among the last to still eat hardtack as a significant part of their normal diet. Originally imported as a food product that could endure the rigors of transportation throughout Alaska, hardtack has remained a favored food even as other, less robust foods have become more readily available. Alaskan law requires all light aircraft to carry "survival gear", including food. Therefore, the blue-and-white Sailor Boy Pilot Bread boxes are ubiquitous at Alaskan airstrips, in cabins, and in virtually every village. Unlike the traditional hardtack recipe, Sailor Boy Pilot Bread contains leavening and vegetable shortening. Hardtack is also a common pantry item in Hawaii, and The Diamond Bakery's "Saloon Pilot" cracker is available there in grocery and convenience stores. The round hardtack crackers are available in large- and small-diameter sizes. Those who buy commercially baked hardtack in the contiguous US are often those who stock up on long-lasting foods for disaster survival rations, though these usually take the form of food ration bars or freeze dried meals rather than traditional hardtack. Many other people who currently buy or bake hardtack in the US are Civil War re-enactors. The 3rd US Regular Infantry Reenactors, for example, often cook many recipes during their reenacting camps, to include hardtack.
=== Effects on sugar absorption and insulin secretion === Gymnemic acid compounds in Gymnema sylvestre can also attach to receptors on the intestinal walls, helping to reduce absorption of sugar molecules in the gut. This process can lower blood sugar and promote insulin secretion and release. However, its antidiabetic properties were not confirmed in rats.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.